Dermatology

Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.

In a recent American Academy of Dermatology survey, it was revealed that 52% of Gen Z adults ages 18 to 26 are unaware of key sunburn risks, such as increased skin cancer risk and premature aging.

Patients with AD often experience different degrees of itch and lesions, with some expressing more severity than others.

The FDA has approved six with dermatologic indications and more are in late-stage trials.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.

Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.

Adults and children with atopic dermatitis experience worse anxiety and depression as disease becomes more severe.

Povorcitinib, an oral JAK1 inhibitor, shows promise in treating prurigo nodularis, a chronic, inflammatory skin disease.

Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.

Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.

John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.

Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.

This makes CSU treatment the sixth approved use globally.

SkinCure Oncology has not yet submitted its data to the FDA for marketing clearance, however once cleared, the new devices will use hybrid laser-generated confocal and photoacoustic imaging in a single fused volumetric image.

The biopharmaceutical company developed VTAMA cream as a once-daily and steroid-free topical cream for both acute treatment and long-term management of AD.

The molecule, DPT0218, was detected during preclinical animal trials.

A recent survey by the American Academy of Dermatology showed that only 13% of Americans plan to use sun protection when going for walks or hikes in cold weather.

New acne guidelines from the American Academy of Dermatology recommend Winlevi (clascoterone), a topical treatment, and Seysara (sarecycline), a narrow-spectrum tetracycline, but qualify the recommendation as conditional because of concerns that the high cost may affect equitable access to treatment,

A review of published research identified only five studies. They showed that telemedicine, particularly for follow-up care, was as effective as in-person care in many respects

A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.

A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia, regardless of age or hair loss severity.

The FDA approved Dermavant Science's Vtama (tapinarof cream) last year as a treatment for plaque psoriasis. Sales have been disappointing, according to press reports. Will Vtama, which has a different mechanism of action than the current batch of topical medications for atopic dermatitis, fare better in the atopic dermatitis market?

The FDA has set a date of July 07, 2024, for Zorvye 0.15% for adults and children six and up with the chronic skin disease atopic dermatitis.

Vtama is a steroid-free cream that works by targeting the aryl hydrocarbon receptor, which plays a role in regulating immune responses.

The updated guidelines include 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments.